Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $69.56 Consensus Price Target from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been assigned an average rating of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat reports. Eleven analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $69.56.

A number of research analysts recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They issued a “buy” rating and a $86.00 price objective for the company. Royal Bank of Canada assumed coverage on shares of Jasper Therapeutics in a report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 price objective for the company. BTIG Research assumed coverage on shares of Jasper Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $90.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Tuesday, June 18th. Finally, TD Cowen started coverage on shares of Jasper Therapeutics in a report on Monday, March 18th. They issued an “outperform” rating for the company.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $19.10 on Wednesday. The company’s 50 day simple moving average is $22.85 and its 200-day simple moving average is $20.66. The company has a market capitalization of $287.65 million, a price-to-earnings ratio of -3.39 and a beta of 2.21. Jasper Therapeutics has a 1 year low of $4.00 and a 1 year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.23. Equities analysts expect that Jasper Therapeutics will post -4.41 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of large investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at $306,000. Ikarian Capital LLC purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at $3,088,000. StemPoint Capital LP purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at $3,794,000. Russell Investments Group Ltd. purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at $2,343,000. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics in the 1st quarter valued at $599,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.